Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 6,215 Shares of Stock
Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 6,215 shares of Xencor stock in a transaction on Tuesday, December 12th. The shares were purchased at an average price of $20.72 per share, with a total value of $128,774.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Xencor, Inc. (XNCR) traded down $0.48 during midday trading on Thursday, hitting $21.01. 194,254 shares of the stock were exchanged, compared to its average volume of 216,189. Xencor, Inc. has a 12-month low of $18.55 and a 12-month high of $28.64.
A number of research firms have weighed in on XNCR. BidaskClub upgraded shares of Xencor from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. Cantor Fitzgerald began coverage on shares of Xencor in a research note on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price objective for the company. Zacks Investment Research upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price target on shares of Xencor in a report on Sunday, November 12th. Finally, ValuEngine downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $30.80.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Emory University purchased a new stake in shares of Xencor during the 2nd quarter valued at about $1,491,000. Virginia Retirement Systems ET AL boosted its holdings in shares of Xencor by 10.0% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock valued at $1,747,000 after acquiring an additional 6,900 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Xencor during the 2nd quarter valued at about $612,000. Vanguard Group Inc. boosted its holdings in shares of Xencor by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after acquiring an additional 90,094 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Xencor by 6.6% during the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock valued at $10,527,000 after acquiring an additional 30,715 shares during the last quarter. 77.62% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 6,215 Shares of Stock” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/insider-buying-xencor-inc-xncr-major-shareholder-purchases-6215-shares-of-stock/1764321.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with Analyst Ratings Network's FREE daily email newsletter.